NCT07353853 Pre-packaged Low-residue Diet for Bowel Preparation in Patients With Inflammatory Bowel Disease
| NCT ID | NCT07353853 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Changhai Hospital |
| Condition | IBD (Inflammatory Bowel Disease) |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000 participants in total. It began in 2026-01-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objectives of this project are twofold: firstly, to evaluate the role of Maifu Changqing® Complete Nutrition Formula Powder in bowel preparation for colonoscopy in patients with IBD; and secondly, to enhance the nutritional support and comfort of bowel preparation for IBD patients.
Eligibility Criteria
Inclusion Criteria: * Age: Adult patients between 18 and 75 years old; * Diagnosis of IBD according to the 2023 Guidelines for the Diagnosis and Treatment of Inflammatory Bowel Disease; * Voluntary participation in this clinical trial and provision of signed informed consent. Exclusion Criteria: * Patients with acute IBD, severe conditions, combined with major bleeding, suspected toxic megacolon, CD with severe intestinal stricture, gastrointestinal obstruction, or other conditions deemed unsuitable for colonoscopy by the physician; * Patients with severe cardiac, pulmonary, hepatic, or renal dysfunction; * History of previous colorectal surgical resection or use of medications that may affect intestinal motility within one week (e.g., antidepressants, sedatives, calcium channel blockers); * History of stroke, spinal cord injury, or psychiatric disorders that impair compliance with bowel preparation and colonoscopy; * Allergy to any component of the administered drugs or meal replacements; * Pregnant or lactating women, and other individuals considered unsuitable for bowel preparation and colonoscopy by the physician.
Contact & Investigator
Yu Bai, M.D.
PRINCIPAL INVESTIGATOR
Changhai Hospital
Frequently Asked Questions
Who can join the NCT07353853 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying IBD (Inflammatory Bowel Disease). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07353853 currently recruiting?
Yes, NCT07353853 is actively recruiting participants. Contact the research team at md.baiyu@foxmail.com for enrollment information.
Where is the NCT07353853 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07353853 clinical trial?
NCT07353853 is sponsored by Changhai Hospital. The principal investigator is Yu Bai, M.D. at Changhai Hospital. The trial plans to enroll 1,000 participants.